soul trial oral semaglutide cardiovascular outcomes results 2025 nejm in High-Risk Type 2 Diabetes: Benefit Confirmed in the SELECT Trial
Description
By Sabina Paglialunga, PhD & Aernout van Haarst, PhD Senior Directors Scientific Affairs Glucagon-Like Peptide-1 (GLP-1) receptor agonists first came to the market in 2005 as a type 2 diabetes mellitus treatment, and they have been making headlines again for their weight reduction effects
Diabetic-Friendly: Does not cause blood sugar spikes
HIGHLIGHT | GLP-1 -
Each patch is made with a comfortable, skin-friendly adhesive that helps it stay securely in place during regular daily activities
NEXTIDA GC Collagen Peptides (Bovine) 10 g **
